Sensex projected to rise 18 pc by end of 2025: Morgan Stanley
In its latest note, the US-headquartered investment bank sees 18 per cent base case upside for the BSE Sensex by the December end.
Drug firm Granules India on Monday said it is ‘voluntarily’ recalling ranitidine tablets used to treat ulcers of the stomach and intestines. The recall is a class II recall, the company added.
“Ranitidine is being recalled by various producers from the US market as they contain unacceptable levels of N nitrosodimethylamine (NDMA). Granules India Ltd is recalling this product voluntarily,” the drug firm said in a filing to BSE.
Advertisement
The move was taken after the company received multiple queries on the news item for recall of ranitidine by the drug firm.
Advertisement
“The quantities being referred in various news websites at this point of time is the last one year sale from Granules India Ltd to Granules USA, subsidiary of the company,” it said.
The exact quantities getting recalled are being estimated, the company said adding that it believes this will not have any material impact on its financials.
The shares of Granules India were trading at Rs 130.25, up 1.75 per cent on BSE at 2.24 pm.
(With in[put from agencies)
Advertisement
